Staidson Beijing Biopharma (300204) - Total Assets
Based on the latest financial reports, Staidson Beijing Biopharma (300204) holds total assets worth CN¥1.28 Billion CNY (≈ $187.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Staidson Beijing Biopharma - Total Assets Trend (2007–2025)
This chart illustrates how Staidson Beijing Biopharma's total assets have evolved over time, based on quarterly financial data. Also see Staidson Beijing Biopharma market capitalisation for the company's overall valuation and market capitalisation.
Staidson Beijing Biopharma - Asset Composition Analysis
Current Asset Composition (December 2025)
Staidson Beijing Biopharma's total assets of CN¥1.28 Billion consist of 20.0% current assets and 80.1% non-current assets. Review Staidson Beijing Biopharma total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.8% |
| Accounts Receivable | CN¥24.13 Million | 1.9% |
| Inventory | CN¥19.30 Million | 1.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥222.33 Million | 17.6% |
| Goodwill | CN¥19.75 Million | 1.6% |
Asset Composition Trend (2007–2025)
This chart illustrates how Staidson Beijing Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Staidson Beijing Biopharma (300204) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Staidson Beijing Biopharma's current assets represent 20.0% of total assets in 2025, a decrease from 46.7% in 2007.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 16.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, a decrease from 24.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 17.6% of total assets.
Staidson Beijing Biopharma Competitors by Total Assets
Key competitors of Staidson Beijing Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Staidson Beijing Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 1.59 | 4.92 |
| Quick Ratio | 1.85 | 1.40 | 4.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥131.32 Million | CN¥83.76 Million | CN¥619.94 Million |
Staidson Beijing Biopharma - Advanced Valuation Insights
This section examines the relationship between Staidson Beijing Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.05 |
| Latest Market Cap to Assets Ratio | 1.24 |
| Asset Growth Rate (YoY) | 10.1% |
| Total Assets | CN¥1.27 Billion |
| Market Capitalization | $1.57 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Staidson Beijing Biopharma's assets above their book value (1.24x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Staidson Beijing Biopharma's assets grew by 10.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Staidson Beijing Biopharma (2007–2025)
The table below shows the annual total assets of Staidson Beijing Biopharma from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.27 Billion ≈ $185.29 Million |
+10.14% |
| 2024-12-31 | CN¥1.15 Billion ≈ $168.22 Million |
-13.71% |
| 2023-12-31 | CN¥1.33 Billion ≈ $194.95 Million |
-20.19% |
| 2022-12-31 | CN¥1.67 Billion ≈ $244.27 Million |
-8.63% |
| 2021-12-31 | CN¥1.83 Billion ≈ $267.35 Million |
-1.57% |
| 2020-12-31 | CN¥1.86 Billion ≈ $271.62 Million |
-0.33% |
| 2019-12-31 | CN¥1.86 Billion ≈ $272.53 Million |
-32.82% |
| 2018-12-31 | CN¥2.77 Billion ≈ $405.65 Million |
+5.46% |
| 2017-12-31 | CN¥2.63 Billion ≈ $384.64 Million |
+11.82% |
| 2016-12-31 | CN¥2.35 Billion ≈ $343.97 Million |
+13.51% |
| 2015-12-31 | CN¥2.07 Billion ≈ $303.03 Million |
+14.29% |
| 2014-12-31 | CN¥1.81 Billion ≈ $265.14 Million |
+15.45% |
| 2013-12-31 | CN¥1.57 Billion ≈ $229.66 Million |
+9.53% |
| 2012-12-31 | CN¥1.43 Billion ≈ $209.69 Million |
+24.67% |
| 2011-12-31 | CN¥1.15 Billion ≈ $168.19 Million |
+333.93% |
| 2010-12-31 | CN¥264.88 Million ≈ $38.76 Million |
+78.07% |
| 2009-12-31 | CN¥148.75 Million ≈ $21.77 Million |
+61.57% |
| 2008-12-31 | CN¥92.07 Million ≈ $13.47 Million |
+11.98% |
| 2007-12-31 | CN¥82.22 Million ≈ $12.03 Million |
-- |
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respi… Read more